Recombinant alpha-interferon and verruca plantaris. A review of the literature.
The authors review the literature and report the mechanisms of action, chemical properties, pharmacokinetics, adverse effects, and clinical studies of recombinant alpha-interferon. The authors believe that clinical trials should be performed with recombinant alpha-interferon therapy on verruca plantaris to prove or disprove the effectiveness of interferon as a potential treatment modality for these commonly encountered lesions.
Johnson
R E
RE
College of Podiatric Medicine and Surgery, University of Osteopathic Medicine and Health Sciences, Des Moines, IA 50312.
Johnson
J C
JC
Kloberdanz
S J
SJ
Morrill
M J
MJ
D002986:Clinical Trials as Topic; D005534:Foot Diseases / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011994:Recombinant Proteins; D014860:Warts / Q000628:therapy*
D007370:Interferon Type I; D011994:Recombinant Proteins